Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Finerenone and Cardiac Remodeling: A randomized, double-blind, placebo-controlled study to evaluate the effects of finerenone on ventricular remodeling
FY 2025-26
Summary
Heart failure often develops when the left side of the heart becomes thicker and stiffer with age. This process of cardiac remodeling makes it harder for the heart to pump blood and increases the risk of heart rhythms and heart disease-related hospitalization. Aldosterone, a hormone in the body, plays a major role in causing this harmful thickening and scarring of the heart muscle.
Finerenone is a new medication that blocks the effects of aldosterone, with fewer side effects compared to previous medications of its class. Large international clinical trials have shown that finerenone can reduce heart- and kidney-related complications in people with diabetes and/or kidney disease. However, we still do not fully understand exactly how finenerone improves heart health, or whether it can reverse harmful structural changes in the heart muscle.
The FINE-MECH trial will answer these questions. In this study, 156 adults with early signs of heart thickening will be randomly assigned to receive either finerenone or a placebo for 12 months, in addition to their usual medical care. We will use cardiac magnetic resonance imaging (MRI), an advanced, non-invasive scan that takes detailed pictures of the heart, to measure changes in heart size, function, and tissue health over time. We will also measure blood markers linked to heart stress.
By comparing these two groups, this study will determine whether finenerone can reverse heart muscle thickening, improve heart chamber structure, and lessen scarring inside the heart. The results of this study will help clarify how this medication improves heart health and support future treatment guidelines for people at risk of developing heart failure.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572676
Name
Hill Braeden
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Finerenone and Cardiac Remodeling: A randomized, double-blind, placebo-controlled study to evaluate the effects of finerenone on ventricular remodeling
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cardiac Magnetic Resonance Imaging; Cardiorenal Syndrome; Cardiovascular Disease; Clinical Epidemiology; Fibrosis/Extracellular Matrix Biology; Heart Failure; Left Ventricular Hypertrophy; Mineralocorticoid Receptor Antagonism; Myocardial Remodeling; Randomized Controlled Trial
Abstract
Heart failure often develops when the left side of the heart becomes thicker and stiffer with age. This process of cardiac remodeling makes it harder for the heart to pump blood and increases the risk of heart rhythms and heart disease-related hospitalization. Aldosterone, a hormone in the body, plays a major role in causing this harmful thickening and scarring of the heart muscle.
Finerenone is a new medication that blocks the effects of aldosterone, with fewer side effects compared to previous medications of its class. Large international clinical trials have shown that finerenone can reduce heart- and kidney-related complications in people with diabetes and/or kidney disease. However, we still do not fully understand exactly how finenerone improves heart health, or whether it can reverse harmful structural changes in the heart muscle.
The FINE-MECH trial will answer these questions. In this study, 156 adults with early signs of heart thickening will be randomly assigned to receive either finerenone or a placebo for 12 months, in addition to their usual medical care. We will use cardiac magnetic resonance imaging (MRI), an advanced, non-invasive scan that takes detailed pictures of the heart, to measure changes in heart size, function, and tissue health over time. We will also measure blood markers linked to heart stress.
By comparing these two groups, this study will determine whether finenerone can reverse heart muscle thickening, improve heart chamber structure, and lessen scarring inside the heart. The results of this study will help clarify how this medication improves heart health and support future treatment guidelines for people at risk of developing heart failure.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hill, Braeden
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~